(NGM: OASM A)
Last week Oasmia Pharmaceutical AB presented the results from a phase I/II
study with Paclical® Vet at the Veterinary European ECVIM-CA Congress in
Budapest.
- The information about Oasmias new product has through the congress reached a
greater public. Several leading veterinary clinics in Europe look forward to
see
Paclical® Vet on the market. There is a huge need of the product, says Kristina
Fritjofsson, Head of Clinical Development at Oasmia.
More information is available at www.ngm.se or www.oasmia.com
Media contact: Maria Lundén +46 (0) 18 50 54 40 e-mail: info@oasmia.com
Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases.
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase. Oasmia is listed on NGM Eguity.
